| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/14/2013 | US20130040388 Cytostatic drug composition |
| 02/14/2013 | US20130040005 Antihypertensive agents |
| 02/14/2013 | US20130040001 Method of processing animal skin |
| 02/14/2013 | US20130039998 Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder |
| 02/14/2013 | US20130039996 Potentiation of cancer chemotherapy by 7-(2, 5- dihydro- 4-imidazo [1, 2-a] pyridine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4 tetrahydro -2-(1-piperidinyl-carbonyl)-pyrrolo [3,2,1-jk] [1,4] benzodiazepine |
| 02/14/2013 | US20130039995 Dermatological compositions comprising at least one reinoid compound, an anti-irritant compound and benzoyl peroxide |
| 02/14/2013 | US20130039989 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide |
| 02/14/2013 | US20130039988 Active pellet excluding chemical additives |
| 02/14/2013 | US20130039987 Method for increasing the solubility of a transcriptase inhibitor composition |
| 02/14/2013 | US20130039986 Silk-Based Ionomeric Compositions |
| 02/14/2013 | US20130039983 Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects |
| 02/14/2013 | US20130039981 Quick Dissolving, Long Acting Zinc Therapeutic Formulations |
| 02/14/2013 | US20130039979 Medication on the basis of 3,3'-diindolylmethane (dim) with high-bioavailability and its use in treatment of human hyperplastic and inflammatory diseases |
| 02/14/2013 | US20130039977 Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof |
| 02/14/2013 | US20130039976 Sodium channel blocker for treatment of loss of superficial sensitivity |
| 02/14/2013 | US20130039975 Liposomes Containing Prostaglandin E1 (PGE1), Formulations Containing Them and Their Use |
| 02/14/2013 | US20130039971 Compositions and methods for inhibition of vegf |
| 02/14/2013 | US20130039970 Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
| 02/14/2013 | US20130039969 Method And Composition For Treating Rhinitis |
| 02/14/2013 | US20130039967 Oral dosage forms |
| 02/14/2013 | US20130039964 Metal entrapped bioactive composites |
| 02/14/2013 | US20130039960 Compositions for reduction of side effects |
| 02/14/2013 | US20130039959 Method of inhibiting hiv and barrier-forming composition therefor |
| 02/14/2013 | US20130039957 Controlled release pharmaceutical compositions of brivaracetam |
| 02/14/2013 | US20130039956 Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| 02/14/2013 | US20130039953 Method for treating a surface with a coating comprising a therapeutic agent and device with treated surface |
| 02/14/2013 | US20130039952 Calcipotriol monohydrate nanocrystals |
| 02/14/2013 | US20130039951 Process Of Preparing A Stabilized And Solubilized Formulation Of Sirolimus Derivatives |
| 02/14/2013 | US20130039949 Immunomodulating compounds and related compositions and methods |
| 02/14/2013 | US20130039945 Anti-Viral Compounds |
| 02/14/2013 | US20130039944 Anti-Viral Compounds |
| 02/14/2013 | US20130039942 Compositions and Methods for Self-Adjuvanting Vaccines against Microbes and Tumors |
| 02/14/2013 | US20130039930 Biomarker for sensitivity to therapy with a notch inhibitor |
| 02/14/2013 | US20130039929 Method treating breast cancer |
| 02/14/2013 | US20130039928 Compositions and methods for reversing corticosteroid resistance or treating respiratory infections |
| 02/14/2013 | US20130039927 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
| 02/14/2013 | US20130039918 Pharmaceutical Composition Using Connective-tissue Growth Factor |
| 02/14/2013 | US20130039908 Prognostic markers and methods for prostate cancer |
| 02/14/2013 | US20130039906 PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE |
| 02/14/2013 | US20130039905 Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease |
| 02/14/2013 | US20130039904 Gambogic acid cyclization analogues, their preparation method and application thereof |
| 02/14/2013 | US20130039895 Mir-150 for the treatment of blood disorders |
| 02/14/2013 | US20130039894 Polypeptides and Use Thereof for Treatment of Traumatic or Degenerative Neuronal Injury |
| 02/14/2013 | US20130039886 Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| 02/14/2013 | US20130039885 Leukotoxin e/d as a new anti-inflammatory agent and microbicide |
| 02/14/2013 | US20130039882 Method to mitigate injury from radiation exposure |
| 02/14/2013 | US20130039881 Combination for the treatment of radiation- or chemotherapy-induced mucositis |
| 02/14/2013 | US20130039880 Cyclodextrin-based polymers for therapeutics delivery |
| 02/14/2013 | US20130039879 Ophthalmic Compositions Containing A Synergistic Combination Of Two Polymers |
| 02/14/2013 | US20130039878 Triple cross-linked collagen, method of manufacturing the same, and use thereof |
| 02/14/2013 | US20130039869 Rosacea treatments and kits for performing them |
| 02/14/2013 | US20130039864 Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof |
| 02/14/2013 | US20130039857 Methods of suppressing cancer, increasing weight loss and/or increasing insulin sensitivity |
| 02/14/2013 | US20130039856 Products and Methods |
| 02/14/2013 | US20130039854 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 02/14/2013 | US20130039848 Fluorescent silica-based nanoparticles |
| 02/14/2013 | US20130039847 Liposomes for pulmonary administration |
| 02/14/2013 | DE102011115173A1 Granule, useful as hot or cold drink, comprises caffeine and sucralose and Stevia/steviol glycoside and/or neohesperidin dihydrochalcone in an enclosed shell of a fat |
| 02/14/2013 | CA2844855A1 Pim kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| 02/14/2013 | CA2844852A1 Pim kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
| 02/14/2013 | CA2844759A1 Method of measuring and monitoring in vivo nitrite levels |
| 02/14/2013 | CA2844742A1 Kinase inhibitor polymorphs |
| 02/14/2013 | CA2844672A1 Chlorobis copper (i) complex compositions and methods of manufacture and use |
| 02/14/2013 | CA2844604A1 Pharmaceutical composition containing diamine derivative |
| 02/14/2013 | CA2844588A1 Pyrido-pyrimidine derivatives |
| 02/14/2013 | CA2844553A1 Cabazitaxel formulations and methods of preparing thereof |
| 02/14/2013 | CA2844525A1 Cyclopropaneamine compound |
| 02/14/2013 | CA2844511A1 Flavonoid compounds, and methods of use thereof |
| 02/14/2013 | CA2844507A1 Jak pi3k/mtor combination therapy |
| 02/14/2013 | CA2844469A1 N- (benzimimdazol-2-yl) -cyclopropane carboxamides as lysophosphatidic acid antagonists |
| 02/14/2013 | CA2844275A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 02/14/2013 | CA2844254A1 Novel macrocycles as factor xia inhibitors |
| 02/14/2013 | CA2843965A1 Inhibiting transient receptor potential ion channel trpa1 |
| 02/14/2013 | CA2843951A1 Use of estetrol as emergency contraceptive |
| 02/14/2013 | CA2843832A1 Novel phthalocyanine derivatives for therapeutic use |
| 02/14/2013 | CA2842885A1 Quinazoline-2,4-dione derivatives |
| 02/14/2013 | CA2842853A1 Novel soft pde4 inhibitors |
| 02/14/2013 | CA2842725A1 Treatment of neurodegenerative diseases |
| 02/14/2013 | CA2842531A1 Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| 02/14/2013 | CA2842526A1 Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| 02/14/2013 | CA2842518A1 Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| 02/14/2013 | CA2842455A1 Method for treating schizophrenia |
| 02/14/2013 | CA2842452A1 Sustained-release preparation of ivabradine or pharmaceutically acceptable salts thereof |
| 02/14/2013 | CA2842123A1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| 02/14/2013 | CA2841874A1 Methods and compositions for modulating voltage-gated calcium channel function |
| 02/13/2013 | EP2557159A1 Prognostic method for pulmonary adenocarcinoma, pulmonary adenocarcinoma detection kit, and pharmaceutical composition for treating pulmonary adenocarcinoma |
| 02/13/2013 | EP2557155A1 Metal salen complex derivative and process for production thereof |
| 02/13/2013 | EP2557086A2 Synthetic heparin pentasaccharides |
| 02/13/2013 | EP2557082A1 Cephem compound having catechol group |
| 02/13/2013 | EP2557080A1 Method for identifying pI3-kinase antagonists |
| 02/13/2013 | EP2557076A1 Anti-leishmania compound and anti-leishmania drug |
| 02/13/2013 | EP2556856A1 6-Cyano-substituted Pyrido[2,3-d]pyrimidines as Adenosin Rezeptor Ligands for the Treatment of Cardiovascular Diseases |
| 02/13/2013 | EP2556840A2 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene |
| 02/13/2013 | EP2556832A1 Uridine and uridine analogues for use in the treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
| 02/13/2013 | EP2556831A1 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine-6-carbonitriles as Adenosin Receptor Ligands for Treatment of Cardiovascular Diseases |
| 02/13/2013 | EP2556830A1 Combined effects of topiramate, ondansetron and naltrexone on alcohol consumption |
| 02/13/2013 | EP2556829A1 Bicyclic labdane diterpenes for use in the treatment of TRPC6 associated diseases |
| 02/13/2013 | EP2556828A1 Composition for amelioration of hypoalbuminemia |
| 02/13/2013 | EP2556827A1 Treatment of neurodegenerative diseases |
| 02/13/2013 | EP2556826A1 Modified-release multiparticulate formulation of diltiazem HCL |